

The Netherlands

Recent and planned developments in pharmaceutical policies 2019

Special topic: patient-based reimbursement decisions

CHANGES IN PRICING	CHANGES IN REIMBURSEMENT
--------------------	--------------------------

01-01-2019 change in VAT on medicines from 6% to 9%

01-01-2019 the patient's out-of-pocket payments on medicines is maximized at € 250 per year per patient



Evoluon in Eindhoven. Designed by Louis Kalff and Leo de Bever. Built between 1964-1966



Groninger museum in Groningen. Designed by Alessandro Mendini. Built between 1990-1994

OTHER CHANGES

Pharmacy preparations (compounding)

In general, a pharmacy preparation of registered brand is allowed under specific conditions according to medicines law. There is public debate these days about the high prices of "new brand" medicines that used to be available as pharmacy preparations. The Minister of Health has stated that in cases of excessive pricing the pharmacy preparations can be seen as an alternative.



Intel Hotel in Zaandam. Designed by Wilfried van Winden. Opened in 2010



Museum De Fundatie in Zwolle. Designed by Bierman Henkel architects. Built in 2012-2013

SPECIAL TOPIC: patient-based reimbursement decisions

If a medicine is not registered in the Netherlands, it is not available on the Dutch market.

1. If a medicine is not included in the reimbursement system, there is no special reimbursement procedure for individual patients.
2. Named patient regulation:
When a medicine is not available in the Netherlands but it is available in foreign countries, the patient has the possibility of obtaining the medicine with a medical certificate. The Health Care Inspection has to approve the import of the medicine. The Health Care Inspection will verify if there is no other registered medicine available.
In general, there is no reimbursement for named patient medicines.
There are two exceptions:
1 The medicine is intended for a disease, which happens 1 : 150,000
2 If you can prove that the medicine is rational pharmacotherapy
3. In case of an early access scheme of a company or compassionate use , there is no special reimbursement procedure for individual patients. In case of new high priced, high need medicines, the Minister is considering a special financial compensation to cover the period between market authorisation and final reimbursement decision in order to grant access to patients.